- Home
- ICCM vs NRXP Comparison
ICCM vs NRXP Comparison
Compare ICCM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- NRXP
- Stock Information
- Founded
- ICCM 2006
- NRXP 2015
- Country
- ICCM Israel
- NRXP United States
- Employees
- ICCM N/A
- NRXP N/A
- Industry
- ICCM
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- NRXP Health Care
- Exchange
- ICCM Nasdaq
- NRXP Nasdaq
- Market Cap
- ICCM 61.1M
- NRXP 58.5M
- IPO Year
- ICCM N/A
- NRXP N/A
- Fundamental
- Price
- ICCM $1.06
- NRXP $2.63
- Analyst Decision
- ICCM Strong Buy
- NRXP Strong Buy
- Analyst Count
- ICCM 1
- NRXP 4
- Target Price
- ICCM $2.00
- NRXP $29.25
- AVG Volume (30 Days)
- ICCM 1.9M
- NRXP 530.9K
- Earning Date
- ICCM 08-13-2025
- NRXP 08-18-2025
- Dividend Yield
- ICCM N/A
- NRXP N/A
- EPS Growth
- ICCM N/A
- NRXP N/A
- EPS
- ICCM N/A
- NRXP N/A
- Revenue
- ICCM $2,787,000.00
- NRXP N/A
- Revenue This Year
- ICCM $62.11
- NRXP N/A
- Revenue Next Year
- ICCM $142.91
- NRXP $231.16
- P/E Ratio
- ICCM N/A
- NRXP N/A
- Revenue Growth
- ICCM N/A
- NRXP N/A
- 52 Week Low
- ICCM $0.48
- NRXP $1.10
- 52 Week High
- ICCM $1.66
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- ICCM 57.34
- NRXP 49.14
- Support Level
- ICCM $1.01
- NRXP $2.26
- Resistance Level
- ICCM $1.12
- NRXP $2.81
- Average True Range (ATR)
- ICCM 0.07
- NRXP 0.24
- MACD
- ICCM 0.02
- NRXP 0.02
- Stochastic Oscillator
- ICCM 47.92
- NRXP 53.62
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.